Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

PURPOSE: Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-α versus IFN-α m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rini, Brian I., Halabi, Susan, Rosenberg, Jonathan E., Stadler, Walter M., Vaena, Daniel A., Archer, Laura, Atkins, James N., Picus, Joel, Czaykowski, Piotr, Dutcher, Janice, Small, Eric J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860433/
https://ncbi.nlm.nih.gov/pubmed/20368558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.5561
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados